Cargando…

Predicting the course of Alzheimer’s progression

Alzheimer’s disease is the most common neurodegenerative disease and is characterized by the accumulation of amyloid-beta peptides leading to the formation of plaques and tau protein tangles in brain. These neuropathological features precede cognitive impairment and Alzheimer’s dementia by many year...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iddi, Samuel, Li, Dan, Aisen, Paul S., Rafii, Michael S., Thompson, Wesley K., Donohue, Michael C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598897/ https://www.ncbi.nlm.nih.gov/pubmed/31254120 http://dx.doi.org/10.1186/s40708-019-0099-0

Ejemplares similares

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
por: Li, Dan, et al.
Publicado: (2018)

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention
por: Insel, Philip S, et al.
Publicado: (2020)

Recent developments in Alzheimer's disease therapeutics
por: Rafii, Michael S, et al.
Publicado: (2009)

Advances in Alzheimer’s Disease Drug Development
por: Rafii, Michael S, et al.
Publicado: (2015)

Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease
por: Baldaranov, Dobri, et al.
Publicado: (2023)

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome
por: Rafii, Michael S., et al.
Publicado: (2015)

Early-stage Alzheimer disease: getting trial-ready
por: Aisen, Paul S., et al.
Publicado: (2022)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease
por: Fleisher, Adam S., et al.
Publicado: (2009)

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
por: Insel, Philip S, et al.
Publicado: (2015)

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview
por: Aisen, P.S., et al.
Publicado: (2020)

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
por: Rafii, Michael S., et al.
Publicado: (2023)

Alzheimer's disease therapeutic research: the path forward
por: Aisen, Paul S
Publicado: (2009)

Q & A: The Alzheimer's disease neuroimaging initiative
por: Aisen, Paul S
Publicado: (2011)

Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
por: Ngolab, Jennifer, et al.
Publicado: (2021)

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
por: van Dyck, Christopher H., et al.
Publicado: (2019)

Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

AD Course Map charts Alzheimer’s disease progression
por: Koval, Igor, et al.
Publicado: (2021)

Alzheimer’s disease progression by geographical region in a clinical trial setting
por: Henley, David B, et al.
Publicado: (2015)

Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?
por: Rafii, Michael S
Publicado: (2014)

TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology
por: Jimenez-Maggiora, G.A., et al.
Publicado: (2020)

Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
por: Walter, S., et al.
Publicado: (2020)

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Evaluating the predictive performance of malaria antibodies and FCGR3B gene polymorphisms on Plasmodium falciparum infection outcome: a prospective cohort study
por: Dwomoh, Duah, et al.
Publicado: (2020)

Correction: Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease
por: Jack, Clifford R., et al.
Publicado: (2010)

Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
por: Langford, O., et al.
Publicado: (2020)

Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease
por: Suzuki, Kazushi, et al.
Publicado: (2020)

MRI Characterizes the Progressive Course of AD and Predicts Conversion to Alzheimer’s Dementia 24 Months Before Probable Diagnosis
por: Salvatore, Christian, et al.
Publicado: (2018)

ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trails
por: Jimenez-Maggiora, Gustavo A, et al.
Publicado: (2022)

Heterogeneity in Preclinical Alzheimer’s Disease Trial Cohort Identified by Image-based Data-Driven Disease Progression Modelling
por: Shand, Cameron, et al.
Publicado: (2023)

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study
por: Sato, Kenichiro, et al.
Publicado: (2021)

Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease
por: Johnson, Piers, et al.
Publicado: (2014)

The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years
por: Walter, S., et al.
Publicado: (2020)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

The Computerized Cognitive Composite (C3) in A4, an Alzheimer’s Disease Secondary Prevention Trial
por: Papp, K.V., et al.
Publicado: (2021)

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
por: Moussa, Charbel, et al.
Publicado: (2017)

Predicting Progression of Alzheimer’s Disease Using Ordinal Regression
por: Doyle, Orla M., et al.
Publicado: (2014)

Corrigendum to: ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trials
por: Jimenez-Maggiora, Gustavo A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vjc20f3v28r0hb2gp9r23tnhrb